Fosgonimeton – (2093305-05-4)

Fosgonimeton is an investigational new molecule being evaluated for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

It is a pro-drug of the active metabolite dihexa, which binds to hepatocyte growth factor (HGF) and enhances its activity at the c-Met receptor. Fosgonimeton has shown neuroprotective effects in preclinical models, including reducing amyloid-beta toxicity and improving cognitive function in animal models of Alzheimer’s disease.

Clinical trials have demonstrated its safety and tolerability, with some evidence of potential cognitive benefits, though it failed to meet primary endpoints in a Phase 2/3 trial for Alzheimer’s.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Fosgonimeton is an investigational new molecule being evaluated for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

It is a pro-drug of the active metabolite dihexa, which binds to hepatocyte growth factor (HGF) and enhances its activity at the c-Met receptor. Fosgonimeton has shown neuroprotective effects in preclinical models, including reducing amyloid-beta toxicity and improving cognitive function in animal models of Alzheimer’s disease.

Clinical trials have demonstrated its safety and tolerability, with some evidence of potential cognitive benefits, though it failed to meet primary endpoints in a Phase 2/3 trial for Alzheimer’s.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/Fosgonimeton
https://www.medchemexpress.com/fosgonimeton.html
https://www.medkoo.com/products/48409
https://pubmed.ncbi.nlm.nih.gov/35180125/
https://alzheimersnewstoday.com/news/fosgonimeton-fails-meet-goal-alzheimers-clinical-trial-data/
Other Names

Fosgonimeton [INN], Fosgonimeton [USAN], H91OA9858J

IUPAC Name

[4-[(2S)-3-[[(2S, 3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-2-(hexanoylamino)-3-oxopropyl]phenyl] dihydrogen phosphate

CAS

2093305-05-4

Molecular Weight

584.6

Molecular Formula

C27H45N4O8P

SMILES

CCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(=O)N

No products in the cart.